- Home
- GH vs ACT Comparison
GH vs ACT Comparison
Compare GH & ACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- ACT
- Stock Information
- Founded
- GH 2011
- ACT 1981
- Country
- GH United States
- ACT United States
- Employees
- GH N/A
- ACT N/A
- Industry
- GH Medical Specialities
- ACT Specialty Insurers
- Sector
- GH Health Care
- ACT Finance
- Exchange
- GH Nasdaq
- ACT Nasdaq
- Market Cap
- GH 5.5B
- ACT 5.3B
- IPO Year
- GH 2018
- ACT 2021
- Fundamental
- Price
- GH $41.72
- ACT $36.13
- Analyst Decision
- GH Strong Buy
- ACT Buy
- Analyst Count
- GH 21
- ACT 4
- Target Price
- GH $52.81
- ACT $37.75
- AVG Volume (30 Days)
- GH 2.7M
- ACT 796.2K
- Earning Date
- GH 04-30-2025
- ACT 04-30-2025
- Dividend Yield
- GH N/A
- ACT 2.05%
- EPS Growth
- GH N/A
- ACT 9.98
- EPS
- GH N/A
- ACT 4.44
- Revenue
- GH $773,996,000.00
- ACT $1,216,974,000.00
- Revenue This Year
- GH $19.53
- ACT $3.68
- Revenue Next Year
- GH $21.92
- ACT $4.25
- P/E Ratio
- GH N/A
- ACT $8.20
- Revenue Growth
- GH 28.20
- ACT 4.52
- 52 Week Low
- GH $18.01
- ACT $29.37
- 52 Week High
- GH $52.92
- ACT $37.56
- Technical
- Relative Strength Index (RSI)
- GH 43.79
- ACT 55.56
- Support Level
- GH $38.86
- ACT $35.31
- Resistance Level
- GH $52.92
- ACT $36.95
- Average True Range (ATR)
- GH 2.91
- ACT 0.87
- MACD
- GH -0.74
- ACT 0.04
- Stochastic Oscillator
- GH 20.34
- ACT 50.02
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.